BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Supernus Pharmaceuticals Sets Terms for $75 Million US IPO


4/12/2012 7:13:22 AM

Washington Business Journal by Bill Flook, Staff Reporter

Supernus Pharmaceuticals Inc., which filed for an initial public offering more than a year ago, said Wednesday it expects to sell 5.8 million shares at an estimated price of $12 to $14 apiece.

In a Securities and Exchange Commission filing, the Rockville biotech estimated it would raise $66.4 million in net proceeds through the offering, or as much as $76.9 million if its underwriters fully exercise their over-allotment option. That estimate assumes the company would go public at $13 per share, the midpoint of the price range.

Supernus, a Shire PLC spinoff that specializes in central nervous system drugs and counts Chevy Chase-based New Enterprise Associates Inc. as one of its venture backers, has two products under review at the Food and Drug Administration: SPN-538 and SPN-804, both epilepsy treatments. Its pipeline also includes earlier-stage product candidates in attention deficit hyperactivity disorder and depression. The FDA is set to decide on SPN-538’s approval in July, with a decision for SPN-804 slated for October.

The biotech said it plans to use the bulk of the proceeds — an estimated $42 million – for sales and marketing of those two drugs, assuming their regulatory approval. It said it would also use the cash from the offering to fund ongoing clinical trials and pay down debt.

Supernus, which would trade on the Nasdaq under the ticker symbol SUPN, expects to have 19.7 million shares of its common stock outstanding post-IPO.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES